This week, we’ll discuss phase II results on cabozantinib in patients with advanced bladder cancer. Then, we’ll review a study on behaviors related to COVID-19 prevention among cancer survivors. Lastly, we’ll hear a discussion about the keynote lecture presented at the First International Summit on Interventional Pharmacoeconomics.

Coverage of stories discussed this week on ascopost.com:

Cabozantinib in Platinum-Refractory Metastatic Urothelial Carcinoma

Cancer Survivors Are Adhering to COVID-19–Related Preventive Behaviors, but Continuity of Care May Be Impacted